We strive to achieve transition and commercialization success with our product development efforts, and this often results in the spin-out of new companies to focus on commercialization of these promising technologies.
One of our major successful commercialization achievements is the development, marketing, and sales of commercial software products CFD-ACE and CFD-FASTRAN. These products are used by more than 500 hundred organizations worldwide, including Fortune 500 companies, National Labs, and Universities. Most of the development of these products was funded by SBIR and STTR projects. In 2004, CFD Research spun off its Software Products to a global software company.
SynVivo’s microfluidic tissue/organ-on-chip platform provides biologically realistic in vitro microenvironments to enable better prediction of human-relevant responses for drug development and personalized medicine applications. Complex in vivo microvascular environments including scale, morphology, hemodynamics, and cellular architecture are re-created in vitro. Validated models include Tumor, Blood blood-brain barrier, Inflammation, and various Toxicology models including the Air-Liquid Interface model for Lung. See www.synvivobio.com for more information on products and services.
SemanticGuard protects business-critical software from cyber threats with next-generation application security. SemanticGuard’s GUARDx platform safeguards businesses from cyber-attacks intended to steal data, disrupt operations, and shut down businesses. While traditional application security companies attempt to detect constantly evolving threats, GUARDx focuses on application-specific protection. GUARDx’s “inside-out” approach leads to faster response times, lower bandwidth requirements, lower false positive rates and reduced labor overhead. Visit www.semanticguard.com for more information.
TheraVista supports Patient Apps and the Clinician Web Portal for physical rehabilitation with gaming, self-management, and remote monitoring elements to improve accessibility and compliance with rehabilitation. The novelty of our approach is that it focuses on making rehabilitation exercises fun, and easier to perform at home while being remotely monitored by a clinician. Visit www.theravista.health for more information.
PoP Therapeutics is a preclinical-stage biopharmaceutical company solving the greatest unmet challenges in oncology by developing differentiated and novel therapeutic candidates. Our lead drug candidates are small molecules targeting pancreatic cancer and metastasis mechanisms through a novel protein target. Visit www.poptherapeutics.org for more information.
Ranalia Biotech is dedicated to delivering cutting-edge, point-of-use testing solutions for agricultural and environmental applications. Our mission is to empower farmers to thrive, by mitigating risks associated with pathogens, genetic resistance, and other factors that impede optimal crop growth. Further, we aim to address post-harvest diagnostics through our innovative approach to ensure sustainable and resilient farming practices. For more information: www.ranalia.com.
Kalm Therapeutics is pioneering a breakthrough in eczema treatment. Kalm’s controlled release eczema wrap (CREW) utilizes Continuous Dose technology to deliver an easy-to-use natural treatment for eczema. For more information, please see our press article: Introducing Kalm Therapeutics (Kalm Tx): Pioneering a Breakthrough in Eczema Treatment – CFD Research (cfd-research.com) and kalmtherapeutics.com.
